Shingles Vaccine Linked to Reduced Dementia Risk, Especially in Women: New Study Reveals
A widely administered vaccination may offer a surprising benefit: protection against dementia. Groundbreaking research utilizing UK health data indicates that the shingles vaccine is associated with a significantly lower risk of developing dementia, with a particularly pronounced effect observed in women.
Dementia represents a growing global health crisis as populations age. This new study, published in the journal Nature, offers a potential avenue for preventative care, leveraging an existing public health program. Researchers evaluated a “natural experiment” created by a nationwide vaccination program, revealing a compelling connection between vaccination and cognitive health.
A ‘Natural Experiment’ Unveils Protective Effects
The study’s innovative design centered around a unique circumstance in Wales. Researchers compared two cohorts: individuals born between 1925 and 1933, who were too old to receive the shingles vaccine when it became available due to limited initial doses, and those born after, who were eligible under the British Ministry of Health’s NHS program introduced in 2013. This separation by birthdate allowed for a seven-year follow-up period with two comparable groups.
The analysis, conducted by an American-German research team, demonstrated that vaccinated individuals experienced a 20 percent reduction in dementia diagnoses compared to their unvaccinated counterparts. This translates to a 3.5 percentage point decrease in the probability of diagnosis across all genders. Notably, the protective effect was more substantial in women, with a 5.6 percentage point reduction. While the study did not find a statistically significant connection for men, the overall findings are considered highly relevant.
How Could a Shingles Vaccine Protect Against Dementia?
The precise mechanisms behind this potential protection remain unclear, but researchers suggest several possibilities. One theory centers on preventing shingles outbreaks themselves, while another points to a broader immune-modulating effect of the vaccine. “Both the prevention of shingles diseases and an immune-modulating effect of the vaccine itself are conceivable,” one analyst noted.
Further bolstering these findings, a separate analysis of medical records from over 100 million people in the United States (spanning 2007-2023) revealed a heightened risk of dementia years after a second shingles outbreak. This underscores the role of the varicella-zoster virus – the virus that causes both shingles and chickenpox – in neurodegenerative processes.
Both Live and Inactivated Vaccines Show Promise
According to the British study, both live and inactivated shingles vaccines appear to reduce the reactivation of the virus, and consequently, the risk of dementia. After accounting for over 400 variables, researchers observed a risk reduction of 27 to 33 percent within three years of vaccination.
Pascal Geldsetzer from Stanford University explained that the virus can remain dormant for years. “Sometimes, however… ‘it is completely reactivated,’” he stated, adding that these reactivations – characterized by burning pain, blisters, and rashes – may cause long-term brain damage. Vaccination, therefore, could be a crucial preventative measure.
Currently, an inactivated herpes zoster vaccine is recommended in Germany for individuals aged 60 and over, as well as those in high-risk groups since 2018.
This research offers a compelling new perspective on dementia prevention, highlighting the potential of existing vaccines to address this growing public health challenge. While further investigation is needed to fully understand the underlying mechanisms and confirm these findings across diverse populations, the initial results are undeniably promising.
